Xeltis is in Swiss Venture Capital Report
Xeltis was in the spotlight this week in the latest Swiss Venture Capital Report, the reference publication for investment in Swiss start-ups. The sector achieved new record overall investment levels and financing rounds last year.
A profile of CEO Laurent Grandidier highlighted how Xeltis’ proven ground-breaking technology has persuaded investors to finance the company in a CHF52 million/EUR45 million round. It was the third-largest in Switzerland last year, setting a European record for medtech startups in 2017.
The report attributed the success to the “forward-looking management of the CEO, who is already working to position the company for the next milestones. The 42-year-old does not see himself as a typical manager: ‘I’m 200% entrepreneur.’”
Click here to access the full report.